Prevalence and risk factors of COVID-19 infection, mortality, and post-infection lung fibrosis in patients with type 2 diabetes: a cross-sectional study.

Autor:	Farah R; Nephrology Division, Department of Internal Medicine, School of Medicine, University of Jordan, Amman, Jordan., Al-Hawari H; Endocrinology Division, Department of Internal Medicine, School of Medicine, University of Jordan, Amman, Jordan., Albtoush A; Pulmonary Division, Department of Internal Medicine, School of Medicine, University of Jordan, Amman, Jordan., Nofal A; School of Medicine, University of Jordan, Amman, Jordan., Hyasat TB; School of Medicine, University of Jordan, Amman, Jordan., Abu Jabeh RAH; School of Medicine, University of Jordan, Amman, Jordan., Suboh LT; School of Medicine, University of Jordan, Amman, Jordan., Toubasi AA; Pulmonary Division, Department of Internal Medicine, School of Medicine, University of Jordan, Amman, Jordan., Eqrai TF; Department of Internal Medicine, The University of Jordan, Amman, Jordan., Abufaraj M; Department of Special Surgery, School of Medicine, University of Jordan, Amman, Jordan.
Jazyk:	angličtina
Zdroj:	The Journal of international medical research [J Int Med Res] 2023 Sep; Vol. 51 (9), pp. 3000605231198413.
DOI:	10.1177/03000605231198413
Abstrakt:	Objectives: The clinical course of coronavirus disease 2019 (COVID-19) infection is often aggressive, with unfavorable outcomes for those with comorbidities such as type 2 diabetes mellitus (T2DM). We aimed to assess the prevalence and risk factors of COVID-19 infection, mortality, and post-infection lung fibrosis in patients with COVID-19 infection who had T2DM. Methods: In this cross-sectional study, we included adult patients with T2DM who attended an endocrinology clinic and underwent testing for COVID-19 infection. Results: Among 1039 included patients, the mean age was 59.5 ± 11.0 years and 429 (41.3%) were men. Overall, 87.1% of patients had received COVID-19 vaccination and 32.3% had confirmed COVID-19 infection. The COVID-19-related mortality was 3.0% and rate of post-COVID-19 lung fibrosis was 19.1%. Vaccination was associated with lower COVID-19-related mortality (odds ratio [OR]: 0.03, 95% confidence interval [CI]: 0.0-0.3) and post-COVID-19 lung fibrosis risk (OR: 0.3, 95% CI: 0.1-0.9). Conclusion: Patients with T2DM exhibited a high prevalence of COVID-19 infection and associated mortality. However, COVID-19 vaccines were beneficial in reducing the risks of COVID-19-related mortality and post-infection lung fibrosis in these patients. COVID-19 vaccines and boosters are recommended for patients with T2DM. Further studies involving larger study populations are necessary to validate these findings.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu